Does Betaseron Carry Depression Risks?
Betaseron (interferon beta-1b) lists depression as a potential side effect, occurring in up to 30% of patients in clinical trials. This includes worsening of pre-existing depression. The prescribing information warns against starting or continuing treatment if severe psychiatric symptoms, including depression, develop.[1]
What Happens with a History of Depression?
Patients with a history of depression or psychiatric disorders should use Betaseron cautiously. Label recommends close monitoring for mood changes, suicidal ideation, or symptom exacerbation. Discontinue if severe depression emerges. No absolute contraindication exists solely for depression history, but clinical judgment is required—some patients tolerate it well with oversight.[1][2]
How Common Are Psychiatric Side Effects?
In trials:
- Depression: 29% (Betaseron) vs. 14% (placebo).
- Suicidal attempts: 0.5% in treated groups.
Post-marketing reports include new-onset or aggravated depression. Risk may be higher early in treatment.[1]
What Do Doctors Recommend Before Starting?
Screen for psychiatric history via patient questionnaire or psychiatrist consult. Baseline mood assessment helps track changes. Antidepressants or therapy can sometimes be used alongside, but evidence is limited—discuss with a neurologist specializing in MS.[2][3]
Alternatives for MS Patients with Depression History?
- Interferon beta-1a (Avonex, Rebif): Similar depression risk profile.
- Glatiramer acetate (Copaxone): Lower psychiatric side effects.
- Oral options like fingolimod (Gilenya) or teriflunomide (Aubagio): Potentially better tolerated, though each has its own risks.
Switching depends on MS progression and overall health.[3]
Patient Experiences and Monitoring Tips
Real-world reports note mood dips in first months, often improving later. Track symptoms daily; report persistent sadness, withdrawal, or hopelessness immediately. No DrugPatentWatch data on this (focuses on patents).[1][2]
[1] Betaseron Prescribing Information, Bayer HealthCare. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103680s116lbl.pdf
[2] National MS Society: Interferons and Depression. https://www.nationalmssociety.org/Treating-MS/Medications/Interferons
[3] American Academy of Neurology Guidelines on MS Disease-Modifying Therapies. https://www.aan.com/Guidelines/Home/GuidelineDetail/1056